Statement of Principles concerning atrial fibrillation and atrial flutter (Reasonable Hypothesis) (No. 1 of 2023)

The central legal-scientific concept in the instrument is the “reasonable hypothesis” connection between AF/AFL (including death from AF/AFL) and relevant service. The instrument’s title and operating clauses indicate that presence of at least one enumerated factor, together with a relationship between that factor and the person’s relevant service, is the minimum necessary to raise that reasonable hypothesis (title, s8-s9, s10(1)). The instrument does not itself define the legal test “reasonable hypothesis”; rather, it operationalises that test by identifying factors the RMA considers, based on its view of the medical evidence, sufficient to meet it for AF/AFL claims against the VEA/MRCA pathways (s8-s9).

Key medical concepts are defined in clinical terms. The instrument provides a clinical definition of atrial fibrillation and atrial flutter, including electrocardiographic and symptomatic features and noting paroxysmal, persistent and permanent forms (s7(2) and notes). It treats death from AF/AFL as including deaths from a terminal event or condition to which AF/AFL contributed (s7(6)-(7) and Schedule definition of terminal event).

The instrument enumerates a broad, non‑exclusive list of factors that, if present at relevant times, raise the reasonable hypothesis. These factors span cardiac structural disease (valvular heart disease, ischaemic heart disease, cardiomyopathy, infiltrative myocardial disease, neoplasms of the atrium), myocarditis (viral and non‑viral), pericarditis, heart failure, conduction system disease (sick sinus syndrome), thromboembolic events, endocrine disease (specific thyroid conditions), pulmonary disease (COPD, asthma), metabolic disease (longstanding diabetes, overweight/obesity), renal disease (chronic renal failure), substance exposures (quantified alcohol consumption, binge drinking, specified drugs, smoking pack‑years), iatrogenic and treatment factors (systemic chemotherapy, specified glucocorticoid therapy, thoracic or cardiac procedures, non‑cardiothoracic surgery with general/regional anaesthesia), physical activity extremes (longstanding strenuous activity or prolonged inability to undertake activity), acute insults (sepsis, ICU admission, mechanical ventilation, blunt/penetrating chest trauma), environmental exposures (ambient chronically or highly polluted air defined by PM2.5/PM10 thresholds), and others (gastro‑oesophageal reflux disease, obstructive sleep apnoea) (s9; Schedule 1 definitions). The instrument also treats the inability to obtain appropriate clinical management as a factor for clinical worsening (s9(86) / later).

The instrument operationalises timing and thresholds: many factors require defined look‑back periods (for example, alcohol average ≥100 g/week for at least five continuous years prior to onset; pulmonary thromboembolism within 30 days before onset; thoracic or invasive cardiac procedure within 1 year before onset; non-cardiothoracic surgery with anaesthesia within 30 days; certain drug exposures within 7 days; systemic chemotherapy at time of onset) (s9; Schedule 1). Several factors contain conditional clauses about cessation, e.g., smoking cessation must have been within five years of onset for the smoking factor to apply (s9 and Schedule 1). For several factors the instrument cross‑references specific agent lists or dose thresholds presented in the Dictionary (e.g., specified list of drugs: adenosine, dobutamine, milrinone; equivalent glucocorticoid therapy table; low‑dose aspirin defined as 325 mg or less) (Schedule 1).

Finally, the Statement’s legal mechanics include cross‑reference and precedence: where a factor refers to an injury or disease that is the subject of another RMA Statement of Principles, that other Statement applies in accordance with its terms as amended from time to time (s11). The instrument also indicates that ICD‑10‑AM coding is acknowledged but that the statutory meaning for the instrument is the clinical description in subsection 7(2) (s7(3)-(4)).

Directly, the instrument applies to persons making claims under relevant provisions of the veterans’ compensation schemes: claims to which section 120A of the VEA or section 338 of the MRCA apply (s5). The Schedule defines “relevant service” to include operational service, peacekeeping service, hazardous service, British nuclear test defence service under the VEA, and warlike or non‑warlike service under the MRCA. That means the human population affected is veterans and members who rendered such forms of service and who either suffer AF/AFL or died with AF/AFL contributing (s5; Schedule definition of relevant service).

Practically, the instrument changes the evidential and medical framework that decision‑makers and clinicians must use when assessing service connection for AF/AFL in the veterans’ context. Decision‑makers (Departmental medical officers, claims assessors, veterans’ advocates, and review tribunals that apply the VEA/MRCA framework) will consult this Statement when determining whether the reasonable hypothesis threshold is met. The instrument cross‑references other Statements of Principles where relevant; therefore, practitioners preparing medical evidence must be aware of both this Statement and other applicable Statements (s11).

Medical practitioners who provide opinions for claims are affected by the instrument’s definitions and thresholds. For example, to support a claim based on alcohol exposure a treating physician needs to document alcohol consumption quantitatively (average ≥100 g/week for five continuous years) or to support a glucocorticoid‑related claim must document cumulative dose and average daily rates consistent with the “equivalent glucocorticoid therapy” table in Schedule 1. Environmental or occupational health experts may be required where factors such as ambient chronically or highly polluted air exposure are relied upon, because the Dictionary defines specific particulate matter thresholds (Schedule 1).

Claimants and their representatives are affected in practical ways: to make a claim that AF/AFL is related to service, evidence must show at least one listed factor and that the factor is related to the person’s relevant service (s9; s10(1)). For factors limited to material contribution or aggravation (subsections 9(45)-9(89)), the claimant’s AF/AFL must have pre‑existed before or during service and that service must have materially contributed to or aggravated it (s10(2)). The instrument therefore affects the documentary and medical records claimants should compile: service medical records, pre‑service and post‑service clinical records, surgical and procedural notes, medication prescriptions and dosages, diagnostic tests, environmental monitoring records, and lifestyle history (alcohol, smoking, BMI, physical activity).

Indirectly, other stakeholders such as insurers, employers with defence personnel, rehabilitation providers, and tribunals that review administrative decisions will need to incorporate the Statement in assessing causation and in framing questions to medical experts. Where a listed factor refers to another Statement of Principles, the interaction may require parties to obtain the other RMA Statement and follow its criteria (s11). The Statement also affects expert witnesses: the Dictionary’s technical thresholds and definitions require experts to address specific metrics (e.g., PM2.5, pack‑years, cumulative glucocorticoid dosing) rather than offer purely qualitative opinions.

The instrument itself does not create new statutory offences, nor does it set out payment entitlements; rather, it establishes medical criteria that operate within the existing claims processes under the VEA and MRCA (s5, s8-s9). The primary duty it imposes is on decision‑makers and those preparing medical evidence to apply the RMA’s listed factors and the Dictionary when assessing whether a reasonable hypothesis exists that AF/AFL or death from AF/AFL is connected with relevant service. The Application clause says it “applies to a claim” under specified statutory sections (s5), which in practice means that assessors considering such claims should use the Statement as the medical criteria for causation.

For claimants, the Statement reproduces the minimum evidentiary criteria they must meet to raise a reasonable hypothesis: presence of at least one enumerated factor, and a relationship between that factor and the claimant’s relevant service (s9; s10(1)). Where factors are conditional or limited to material contribution or aggravation (subsections 9(45)-9(89)), the claimant’s AF/AFL must have been suffered or contracted before or during service and the service must have materially contributed to or aggravated the condition (s10(2)). The claimant has the right to rely on this instrument in their submissions and to adduce medical evidence tied to the instrument’s definitions and look‑back windows.

Medical practitioners giving opinions have duties of particular specificity imposed by the Statement’s content. They must, if relying on any of the listed factors, document the relevant measures and windows that the Dictionary requires: e.g., quantify alcohol consumption against the Australian standard of 10 g per drink and the ≥100 g/week for five years threshold; document BMI or waist circumference thresholds; show glucocorticoid cumulative dose and average daily rate if relying on that pathway; specify drug exposures and timing; document air pollution exposures against PM2.5/PM10 thresholds (s9; Schedule 1). When a listed factor refers to another Statement of Principles, the duty to apply that other Statement’s criteria follows (s11).

Decision‑makers exercising duties under the VEA and MRCA will apply the Statement to the reasonable hypothesis question. The instrument expressly states the RMA’s view that there is sound medical‑scientific evidence linking AF/AFL and relevant service (s8). That is an evidentiary posture rather than a procedural rule: it is the basis for the RMA determining the Statement. The rights of claimants to have their claims assessed remain governed by the VEA/MRCA processes; the Statement supplies the medically framed lens.

Procedural rights such as merits review, judicial review, or internal reconsideration are not described in this instrument. The instrument does not itself prescribe decision timelines, compensation entitlements, or appeal rights; those are governed by the VEA and MRCA statutory frameworks. The instrument’s role is technical: it constrains and clarifies the medical factors that meet the reasonable hypothesis standard for AF/AFL claims (s5, s8-s11).

The Statement does not set out criminal penalties, civil sanctions or administrative fines. The instrument’s operative effect is evidentiary and diagnostic within the VEA/MRCA claim processes. It prescribes medical criteria and definitions to be used when raising the reasonable hypothesis that AF/AFL is related to relevant service (s5, s8-s9). The text contains no enforcement provisions, no compliance regime for third parties, and no prescribed sanctions for non‑compliance within the instrument itself.

Enforcement, in the sense of application, occurs through the claims assessment apparatus established by the VEA and MRCA. The Statement “applies to a claim to which section 120A of the VEA or section 338 of the MRCA applies” (s5). That means its force is evidential for the purposes of adjudication by agencies or bodies who make decisions under those statutory sections , they will use the Statement’s medical criteria when determining whether a reasonable hypothesis exists. The instrument does not, however, specify which decision‑maker enforces it or the mechanisms of enforcement; those matters remain governed by the procedural and review provisions of the VEA and MRCA (s5).

Because the instrument is silent on penalties, the compliance consequences are indirect: failure to adduce evidence meeting the Statement’s criteria may mean a claimant cannot raise the required reasonable hypothesis and thus may have their claim rejected under the normal claims processes. Conversely, meeting the Statement’s factor thresholds should, at minimum, satisfy the RMA’s medical criteria for a reasonable hypothesis, subject to the decision‑maker’s factual application. The instrument also cross‑references other Statements where appropriate (s11), which means that if a factor refers to another covered disease, decision‑makers will apply that other Statement’s criteria; non‑compliance with either instrument’s requirements may affect the outcome of a claim.

In sum, the instrument is not an enforcement instrument in the criminal or regulatory sense. Its practical enforcement is through claim determinations under the VEA/MRCA frameworks, and the consequences of non‑alignment with its prescribed criteria are adjudicative (e.g., adverse claim outcomes) rather than penal sanctions set out in the Statement itself (s5, s8-s11).

The Statement is made under subsection 196B(2) of the Veterans' Entitlements Act 1986 (s3) and expressly applies to claims under section 120A of the VEA and section 338 of the MRCA (s5). Its statutory function is therefore to provide the RMA’s medical view which decision‑makers use when applying the reasonable hypothesis standard under those Acts. The instrument does not purport to alter the text of the VEA or MRCA; instead, it supplies medical criteria for use in adjudicating causation questions that arise under those statutes (s3, s5, s8-s9).

The instrument anticipates overlap with other Statements of Principles. Section 11 provides that where a factor referred to in section 9 relates to an injury or disease already covered by another Statement of Principles, “the factors in that Statement of Principles apply in accordance with the terms of that Statement of Principles as in force from time to time.” That creates an interactional rule: a listed factor that is actually an injury/disease treated elsewhere will be adjudicated under that other Statement’s terms (s11). Practically, this requires claimants, advisers, and decision‑makers to consult multiple RMA Statements where cross‑referencing occurs.

The Statement also interacts with clinical classification standards. It notes that AF/AFL attract ICD‑10‑AM code I48 but clarifies that for the purposes of this Statement the clinical definitions provided in subsection 7(2) govern (s7(3)-(4)). The instrument therefore recognises external diagnostic coding schemes but prioritises its own clinical description for legal operation.

Several of the factors require data or thresholds that intersect with other regulatory or scientific frameworks. For example, the definitions of ambient chronically polluted air and ambient highly polluted air depend on particulate matter concentration thresholds for PM2.5 and PM10 (Schedule 1). Establishing exposure under those definitions may require reference to air quality monitoring data, environmental law determinations, or public health data governed by environmental agencies rather than the RMA. Similarly, some factors refer to specific pharmacological agents and dose thresholds (e.g., specified list of drugs, systemic chemotherapy examples, equivalent glucocorticoid therapy table); these interactions may require alignment with therapeutic practice, pharmaceutical records, hospital administration records, and professional standards.

The instrument does not displace other statutory duties or entitlements under the VEA/MRCA, nor does it modify administrative law rights of review. It is an evidentiary instrument to be used within the decision‑making processes of those Acts (s5, s11). Where a factor refers to another RMA Statement, the terms of that Statement (which are themselves instruments made under subsection 196B(2) VEA) will apply as in force from time to time (s11), so interactions can evolve as new or amended Statements are made.

Finally, because the Statement sets time windows and specific thresholds (many in Schedule 1), its application may require evidence that originates from outside the veterans’ claims system: surgical and procedure records, pathology and imaging, environmental monitoring, pharmacotherapy records, and occupational health records. That cross‑sector evidence requirement can create practical interface issues between DVA processes and other regulatory or record‑holding entities.

This instrument is dated 23 December 2022, and it commences on 23 January 2023 (front matter and s2). It explicitly repeals the Statement of Principles concerning atrial fibrillation and atrial flutter No. 49 of 2014 (Federal Register of Legislation No. F2014L00481) made under subsection 196B(2) of the VEA (s4). The instrument is identified as No. 1 of 2023 and is executed under the Common Seal of the RMA (front matter). The instrument’s authority is stated as subsection 196B(2) of the VEA (s3).

The instrument itself does not contain a detailed amendment schedule or transitional provisions beyond repeal of the earlier Statement. It does not state transitional arrangements for claims lodged before commencement; rather it states it “applies to a claim to which section 120A of the VEA or section 338 of the MRCA applies” (s5). Where questions of temporal application or transitional handling arise in practice, they will be resolved by reference to the VEA/MRCA processes and any administrative guidance from DVA or RMA accompanying the Statement. The Statement’s cross‑reference clause (s11) indicates that other Statements of Principles remain applicable as in force from time to time; therefore, future amendments to other Statements will interact with this instrument without needing further explicit amendment here.

The Schedule (Dictionary) introduces or reconfirms definitions for several technical terms that are central to the Statement’s operation: ambient chronically/highly polluted air, BMI, binge drinking, chronic renal failure, equivalent glucocorticoid therapy (with a table), glucocorticoid therapy as specified, low‑dose aspirin (325 mg or less), MET, MRCA, pack‑year, relevant service, sepsis, specified lists (drugs, thyroid conditions, autoimmune/inflammatory diseases), subclinical hyperthyroidism, spinal cord injury, terminal event, valvular heart disease, and VEA (Schedule 1). These definitions constitute part of the instrument as made and therefore represent the current consolidated terms. Any future amendment to these definitions would require a new RMA Statement or amendment instrument under the enabling subsection.

Because the instrument expressly repeals the 2014 Statement, practitioners should be attentive to differences between the 2014 and 2023 texts when advising clients about older decisions or ongoing claims. The instrument does not set out an exhaustive list of changes from the 2014 Statement; for a full comparative analysis one must obtain the repealed instrument and compare the factors, definitions and timing windows. The RMA’s explanatory materials or the Federal Register of Legislation may carry additional procedural notes or Explanatory Statements that describe why particular changes were made; those materials are not part of the instrument text reproduced here.

The instrument itself contains no litigation history, and it does not name any judicial or tribunal decisions. The Statement is a primary administrative medical instrument and does not cite case law or adjudicative precedents. Because the instrument is new as of 23 January 2023 and expressly repeals the 2014 Statement, any litigation or tribunal decisions that relied on the 2014 Statement would be historical and not recorded within the text of this instrument.

If disputes arise about how the Statement is applied in individual claims, those disputes would occur within the statutory review mechanisms provided by the VEA and MRCA (for example, internal review, Veterans’ Review Board, Administrative Appeals Tribunal, or judicial review in the courts where available). The Statement itself does not supply litigation pathways or precedent; rather it provides medical criteria that decision‑makers and reviewing bodies will apply. Therefore the litigation history relevant to practical application will be generated post‑commencement as claimants test the Statement’s application in contested claims.

Given the absence of cases named or cited in the Statement, analysts and advisers intending to rely on this instrument should monitor decisions of veterans’ review bodies and courts that interpret or apply the Statement’s particular factors, definitions and temporal windows. Such case law will be the source of adjudicative interpretation (for example, whether a particular documentation standard meets the Dictionary’s thresholds, or the evidentiary weight to be attached to environmental exposure data). Until such jurisprudence develops, the Statement stands as a technical administrative standard to be applied by decision‑makers.

The Statement contains many specific thresholds, temporal windows and conditional clauses that materially affect the outcome of claims. These precise formulations are potential “gotchas” for claimants and advisers who rely on imprecise evidence. Key examples follow, grounded in the instrument text and the Schedule of definitions.

• Single‑factor sufficiency threshold: The Statement requires “at least one of the following factors” to exist to raise a reasonable hypothesis (s9). That means a claimant need only rely on one enumerated factor, but that factor must be demonstrably present and related to relevant service (s10(1)). Overlooking a missing element in a single factor (for example timing or dose thresholds) will defeat the claim.

• Timing windows are strict: Many factors have explicit look‑back windows. Examples include pulmonary thromboembolism within 30 days before onset (s9), thoracic or invasive cardiac procedures within 1 year (s9), non‑cardiothoracic surgery with anaesthesia within 30 days (s9), taking a specified list of drugs within 7 days (s9), and systemic chemotherapy “at the time of” onset (s9). Claims relying on such factors need contemporaneous records that establish the timing in relation to clinical onset or worsening.

• Dose and duration thresholds: The instrument quantifies exposures. Alcohol requires an average of at least 100 g/week for a continuous period of at least 5 years prior to onset (s9 and Schedule 1 note about 10 g per standard drink). Glucocorticoid therapy requires specified cumulative doses and average rates or an equivalent glucocorticoid (Schedule 1 and s9). Low‑dose aspirin is defined as 325 mg or less (Schedule 1). Failure to document dose or duration precisely can fail to meet the factor.

• Conditional cessation clauses: Several factors include clauses tied to cessation timing. For smoking, the factor applies if smoking reached at least 5 pack‑years before onset and , if cessation occurred , the onset was within five years of cessation (s9 and Schedule 1). Glucocorticoid therapy has a 30‑day post‑cessation window (s9 and Schedule 1). These stop‑dates matter when compiling medical histories.

• Environmental exposure requires objective data: The definitions for ambient chronically polluted air and ambient highly polluted air are expressed in particulate thresholds (PM2.5 annual >25 µg/m3; 24‑hour PM2.5 >50 or PM10 >75 µg/m3) (Schedule 1). Establishing these exposures in relation to a person’s location during their service requires environmental monitoring data, which may not be available or may require expert evidence. The technical nature of these definitions is a practical hurdle.

• Interaction with other Statements: Where a factor refers to an injury or disease covered by another RMA Statement of Principles, that other Statement applies (s11). Failure to consult the other Statement might mean a claimant misses additional or different criteria that govern that factor.

• Pre‑existing disease limitation: Subsections 9(45) to 9(89) (the instrument’s later enumerated factors) apply only to material contribution to, or aggravation of, AF/AFL where the person’s AF/AFL was suffered or contracted before or during (but did not arise out of) the person’s relevant service (s10(2)). Counsel should note that these factors cannot be used to establish primary causation where AF/AFL arose out of service; they are limited to material contribution/aggravation in the pre‑existing disease scenario.

• Clinical worsening vs clinical onset distinctions: The Statement contains separate lists for factors that raise a reasonable hypothesis about clinical onset and those that raise it about clinical worsening (s9 subsections). Advisers should ensure that medical evidence is framed to match whether the claim concerns onset or a worsening event; conflating the two can produce evidentiary gaps.

• “Inability to obtain appropriate clinical management” as a factor: The instrument lists inability to obtain appropriate clinical management as a factor for clinical worsening (s9 near the end). Demonstrating this will require evidence of attempts to access care and the reasons for failure, which may be administrative, geographical, systemic or service‑related; evidentiary standards for this factor are likely to demand contemporaneous records.

• Examples are not exhaustive: The instrument frequently provides examples (for instance, examples of viral myocarditis, examples of invasive cardiac procedures, examples of causes of blunt chest injury). Those examples are illustrative rather than exhaustive; advisers should not assume an example is necessary or exclusive. However, because the instrument supplies particular examples, failure to show how a non‑example fits into the broader descriptor may create issues in adjudication.

• Metric conversions and calculations: The Schedule defines BMI formula, pack‑year calculation, and alcohol per standard drink (10 g). Advisers should ensure calculations and units are consistent with these definitions to avoid evidentiary disputes.

• No penalties but practical consequences: The Statement does not prescribe penalties (see Penalties and enforcement). However, failing to meet its exacting definitions or windows is likely to result in claim refusal on causation grounds, which has material consequences for claimants given the remedial nature of the VEA/MRCA entitlements framework.

For claimants, clinicians and advisers the Statement requires careful documentary preparation that aligns with the instrument’s precise factors, timing windows and definitions. The following is a practical, source‑grounded checklist for compliance when preparing or assessing a claim that relies on this Statement.

1. Identify the statutory claim pathway: Confirm the claim is one to which section 120A of the VEA or section 338 of the MRCA applies (s5). If not, the Statement’s applicability may be limited.

2. Establish the clinical diagnosis: Ensure the diagnosis of atrial fibrillation and/or atrial flutter is documented in clinical records using the clinical definition in subsection 7(2) (s7). Include ECGs, Holter monitoring, cardiology consultation letters and hospital discharge summaries that establish onset date and clinical features.

3. Map onset and worsening dates precisely: The Statement distinguishes “clinical onset” from “clinical worsening” and ties many factors to specific look‑back periods (s9). Supply records that place the clinical onset/worsening precisely in time relative to alleged causal factors.

4. Match factor to Dictionary thresholds: For any relied factor, gather evidence that satisfies the Schedule 1 definition or threshold. Examples:

   • Alcohol: obtain contemporaneous notes or self‑reports quantified against 10 g per standard drink and averaged to demonstrate ≥100 g/week for five continuous years (s9; Schedule 1).
   • Smoking: document cigarettes per day and years to calculate pack‑years; if smoking ceased, show cessation date so the five‑year window can be tested (s9; Schedule 1).
   • BMI/waist circumference: provide height, weight and waist circumference to show BMI ≥25 or waist thresholds (Schedule 1).
   • Glucocorticoids: extract pharmacy or hospital dosing records, calculate cumulative dose and average daily rate, and reference the equivalent glucocorticoid table in the Dictionary (Schedule 1).
   • Environmental pollution: obtain air quality monitoring data, location histories, and expert reports that map PM2.5/PM10 concentrations to the relevant timelines (Schedule 1).
   • Drugs and chemotherapy: obtain medication charts, oncology treatment records to demonstrate exposure to specified agents/doses and temporal relation to onset (s9; Schedule 1).

5. Surgical and procedural evidence: For claims relying on recent procedures, obtain operative reports, anaesthesia records and discharge summaries to demonstrate the type of procedure and its timing: thoracic/invasive cardiac procedures within 1 year, non‑cardiothoracic surgery with anaesthesia within 30 days (s9).

6. Acute events and ICU/sepsis: If relying on sepsis, ICU admission, or mechanical ventilation as factors, ensure ICU notes, discharge summaries and sepsis documentation are included and indicate dates within the 30‑day windows where required (s9; Schedule 1 definition of sepsis).

7. Demonstrate relationship to relevant service: The Statement requires the factor to be “related to the relevant service” (s10(1)). Provide service medical records, deployment records, occupational exposure logs, unit diaries or other service documentation that tie the presence or occurrence of the factor to service. For factors that occurred before or during service but did not arise out of service, and where material contribution or aggravation is relied upon, document how service materially contributed or aggravated the existing AF/AFL (s10(2)).

8. Cross‑reference other Statements of Principles where necessary: If a factor invokes an injury or disease addressed in another RMA Statement, obtain and apply the terms of that other Statement (s11). For example, if relying on a condition that is the subject of another SOP, align evidence with that SOP’s criteria.

9. Provide expert medical opinion framed to the Statement: Ask treating specialists or independent experts to address the Statement directly: identify which listed factor(s) apply, show how the factual evidence meets the Dictionary thresholds, explain the timing, and opine on the relationship to relevant service in terms of the Statement’s standard (i.e., whether the factor and link to service raise a reasonable hypothesis). Experts should reference the specific subsection(s) and Dictionary definitions relied upon.

10. Anticipate challenges on measurement and causation: Because many factors require technical measurement (PM2.5, pack‑years, cumulative dosing), retain or commission appropriate specialists or reports (environmental scientists, addiction specialists, occupational physicians, clinical pharmacologists) to ensure measurement is robust.

11. Document attempts to obtain care if relying on inability to obtain appropriate clinical management: Collect appointment records, referrals, correspondence, and evidence of barriers (e.g., geographical service postings, denial of access, administrative refusals) to show the inability to obtain appropriate care and link that inability temporally to clinical worsening (s9).

12. Keep contemporaneous records: Given the retrospective nature of many factors (smoking history, alcohol history, prior surgeries), contemporaneous notes (service medical notes, civilian GP notes, hospital records) carry weight. Secondary recollection without corroboration may be insufficient for thresholds tied to precise quantities or dates.

13. Prepare submissions that map evidence to the Statement: In the claim submission, create a table or schedule that matches each element of the Statement relied upon to the documentary evidence and relevant statutory subsection (e.g., “SOP s9(14): thoracic surgical procedure , evidence: operative note XX dated DD/MM/YYYY; hospital discharge summary; relates to service: procedure performed while on deployment at Base Y on DD/MM/YYYY”).

14. Monitor Statements and cross‑references for amendments: The Statement and other RMA SOPs can be updated (s11). Regularly check the Federal Register of Legislation and RMA publications for amendments or new guidance that might affect the criteria or the interpretation of cross‑referenced Statements.

Following this compliance-oriented checklist aligns the evidentiary presentation with the RMA’s instrument. The central practical point is to ensure documentary evidence maps precisely to the Statement’s language: timing windows, dose/quantity thresholds, and Dictionary definitions will be determinative in many claims.